Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024:66:175-216.
doi: 10.1007/7854_2023_449.

Microbiota-Gut-Brain Axis and Antidepressant Treatment

Affiliations
Review

Microbiota-Gut-Brain Axis and Antidepressant Treatment

David Antoine Lachmansingh et al. Curr Top Behav Neurosci. 2024.

Abstract

In the treatment of depressive disorders, conventional antidepressant therapy has been the mainstay of clinical management, along with well-established nonpharmacological interventions such as various kinds of psychotherapy. Over the last 2 decades, there has been considerable interest in the role of the gastrointestinal system and its microbiota on brain function, behavior, and mental health. Components of what is referred to as the microbiota-gut-brain axis have been uncovered, and further research has elicited functional capabilities such as "gut-brain modules." Some studies have found associations with compositional alterations of gut microbiota in patients with depressive disorders and individuals experiencing symptoms of depression. Regarding the pathogenesis and neurobiology of depression itself, there appears to be a multifactorial contribution, in addition to the theories involving deficits in catecholaminergic and monoamine neurotransmission. Interestingly, there is evidence to suggest that antidepressants may play a role in modulating the gut microbiota, thereby possibly having an impact on the microbiota-gut-brain axis in this manner. The development of prebiotics, probiotics, and synbiotics has led to studies investigating not only their impact on the microbiota but also their therapeutic value in mental health. These psychobiotics have the potential to be used as therapeutic adjuncts in the treatment of depression. Regarding future directions, and in an attempt to further understand the role of the microbiota-gut-brain axis in depression, more studies such as those involving fecal microbiota transplantation will be required. In addition to recent findings, it is also suggested that more research will have to be undertaken to elicit whether specific strains of gut organisms are linked to depression. In terms of further investigation of the therapeutic potential of prebiotics, probiotics, and synbiotics as adjuncts to antidepressant treatment, we also expect there to be more research targeting specific microorganisms, as well as a strong focus on the effects of specific prebiotic fibers from an individualized (personalized) point of view.

Keywords: Antidepressants; Depression; Fecal microbiota transplantation; Gut microbiota; Microbiota-gut-brain axis; Prebiotics; Probiotics; Psychobiotics; Synbiotics.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Abildgaard A, Elfving B, Hokland M, Wegener G, Lund S (2017) Probiotic treatment reduces depressive-like behaviour in rats independently of diet. Psychoneuroendocrinology 79:40–48. https://doi.org/10.1016/j.psyneuen.2017.02.014 - DOI - PubMed
    1. Ait Chait Y, Mottawea W, Tompkins TA, Hammami R (2020) Unravelling the antimicrobial action of antidepressants on gut commensal microbes. Sci Rep 10(1). https://doi.org/10.1038/s41598-020-74934-9
    1. Alcock J, Maley CC, Aktipis CA (2014) Is eating behavior manipulated by the gastrointestinal microbiota? Evolutionary pressures and potential mechanisms. Bioessays 36(10):940–949. https://doi.org/10.1002/bies.201400071 - DOI - PubMed - PMC
    1. Alfaifi AA, Althemery AU (2022) Sociodemographic characteristics and health-related quality of life of individuals undergoing antidepressant therapy. Sci Rep 12(1). https://doi.org/10.1038/s41598-022-22164-6
    1. Allen AP, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G, Scott L, McLoughlin DM, Cryan JF, Dinan TG, Clarke G (2015) Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J Affect Disord 186:306–311. https://doi.org/10.1016/j.jad.2015.06.033 - DOI - PubMed

MeSH terms

LinkOut - more resources